Copper Peptide GHK-Cu Shows Promise for Treating Inflammatory Bowel Disease

Ulcerative colitis affects millions worldwide, causing chronic intestinal inflammation with limited treatment options. This study explored whether GHK-Cu, a naturally occurring copper-binding peptide with established anti-aging and wound-healing properties, could treat inflammatory bowel disease.

Researchers induced colitis in mice using dextran sulfate sodium (DSS) and treated groups with either GHK-Cu or the standard drug 5-ASA. They used comprehensive methods including histological analysis, protein expression studies, network pharmacology, molecular docking, and cell culture experiments to understand mechanisms.

GHK-Cu treatment dramatically improved disease outcomes. Mice showed reduced weight loss, lower disease activity scores, decreased colon inflammation and shortening, and increased protective goblet cells. The peptide suppressed key inflammatory molecules (TNF-α, IL-6, IL-1β) while restoring crucial intestinal barrier proteins ZO-1 and Occludin that prevent harmful substances from crossing the gut wall.

Mechanistically, GHK-Cu activated SIRT1, a longevity-associated protein that regulates inflammation and cellular stress responses. This activation suppressed phosphorylated STAT3, a transcription factor that drives inflammatory responses and Th17 cell development. Gene silencing experiments confirmed STAT3's central role in GHK-Cu's therapeutic effects on barrier function, though anti-inflammatory effects involved additional pathways.

These findings position GHK-Cu as a promising therapeutic candidate for inflammatory bowel diseases, potentially offering advantages over current treatments through its dual anti-inflammatory and tissue-repair mechanisms targeting fundamental aging-related pathways.